A. Zubrzycka-Sienkiewicz

Program ograniczania późnych skutków RZS Rheumatoid arthritis classification criteria in patients with early undifferentiated arthritis – results of preliminary studies

E. Stanisławska-Biernat, A. Filipowicz-Sosnowska, B. Kwiatkowska, 2007 .

Peficitinib, a JAK Inhibitor, in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate

M. Genovese, A. Kivitz, J. Garg, 2017, Arthritis & rheumatology.

Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease‐Modifying Antirheumatic Drugs in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis

M. Genovese, M. Cardiel, A. Kivitz, 2017, Arthritis & rheumatology.

Efficacy and Safety of ABBV‐3373, a Novel Anti–Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody–Drug Conjugate, in Adults with Moderate‐to‐Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double‐Blind, Active‐Controlled Proof‐of‐Concept Phase IIa Trial

F. Buttgereit, B. Rojkovich, H. Kupper, 2022, Arthritis & rheumatology.